Reproductive issues in adults with congenital heart disease: arrhythmias during pregnancy: importance, diagnosis and therapy

The Thoracic and Cardiovascular Surgeon
H Baumgartner

Abstract

Even in healthy women, increased ectopic activity is commonly seen during pregnancy. Congenital heart defects--whether nonoperated or operated--are, in general, associated with an increased risk of arrhythmias to a greater or lesser extent. During pregnancy, congenital heart disease patients are at increased risk of presenting first time with a symptomatic arrhythmia or, if previously diagnosed, the risk of recurrence of their arrhythmia is increased. Antiarrhythmic therapy should in general be restricted to the presence of intolerable symptoms, hemodynamic compromise or threat to the fetus and to patients in whom the arrhythmia may be life-threatening. The risk/benefit ratio must be considered for both the mother and the fetus. Considerations include the stage of pregnancy as well as possible effects of therapy on labor, delivery, and lactation. Nearly all of the presently available antiarrhythmic drugs are classified as Category C drugs in pregnancy. Thus, we rely on observational reports. Safety data are discussed for various drugs, and recommendations for the treatment of various arrhythmias are presented in this review.

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.